The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Quality-of ...

Celebrating its 75th year of progress toward its mission to cure blood cancer and improve the quality of life of all patients ...

Rarely, leukemia can transform into lymphoma, usually non-Hodgkin lymphoma. This is called Richter's syndrome. Richter's syndrome tends to happen with chronic lymphocytic leukemia (CLL).

If you need help finding counseling services, call the Leukemia & Lymphoma Society at 800-955-4572. Get quality sleep. Chronic lymphocytic leukemia and its treatments can make you feel tired and ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

Melvin Mann, diagnosed with chronic myeloid leukemia in 1994, participated in a clinical trial for Imatinib that extended his ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell lymphoma.

Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with ...